对于MUYTH基因,在携带有两种MUTYH基因拷贝突变的人中,有40%的人的突变与FDA授权检测到的突变不同。这个数字在亚裔美国人中上升到100%,在非洲裔美国人中上升到75%。携带有这两种基因突变的人一生中罹患肠癌的风险几乎是100%。
For BRCA genes, 94% of non-Ashkenazi Jewish individuals and 19% of those of Ashkenazi heritage had a mutation that would be missed. Again, the figures were highest for those of Asian (98%) and African-American (99%) ancestry.
对于BRCA基因,94%的非德系犹太人和19%的德系犹太人携带有可能被遗漏的基因突变。同样,亚裔(98%)和非裔(99%)的比例最高。
"A clinical false-negative result can be incorrectly reassuring, excluding a patient from receiving the preventive care they need based on their risk," he added. "It could be the difference between preventing cancer and developing cancer."
他补充说:“临床假阴性的结果可能是误导性的安慰,使人们不再接受需要基于风险而进行的预防性治疗。人们可能会患上原本可以预防的癌症。”
In response to the findings, 23andMe said in a statement: "The claims made by a competitor that we are returning 'clinical false negatives' is incorrect and a false characterisation of 23andMe's test. Our test is extremely accurate. As part of the FDA authorisation process we've demonstrated over 99% accuracy for the variants we test for in our health product."
【基因检测结果呈阴性可能是"虚假的安慰"】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15